FORM 10-QSB
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For Quarter Ended June 30, 2001
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 0-25238
NATURAL HEALTH TRENDS CORP.
(Exact Name of Small Business Issuer as Specified in its Charter)
Florida 59-2705336
State or other jurisdiction of (I.R.S. Employer
incorporation or organization Identification No.)
5605 N. MacArthur Boulevard, 11 Floor
Irving, Texas 75038
(Address of Principal Executive Office) (Zip Code)
(972) 819-2035
(Issuer's telephone number including area code)
Indicate by check mark whether the issuer (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
The number of shares of issuer's Common Stock, $.001 par value, outstanding as
of July 22, 2001 was 173,623,724 shares.
NATURAL HEALTH TRENDS CORP.
INDEX
Page
Number
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheet as of June 30, 2001
(unaudited) 1
Consolidated Statements of Operations (unaudited)
for the Six months and Three months ended June 30,
2001 and 2000 2
Consolidated Statements of Cash Flows (unaudited)
for the Six months ended June 30, 2001 and 2000 3
Notes to the financial statements 4-6
Item 2. Management's discussion and analysis or plan of
operations 6-9
PART II - OTHER INFORMATION
Item 1 Legal Proceedings 9
Item 2 Changes in Securities and Use of Proceeds 9-10
Item 3 Defaults Upon Senior Securities 10
Item 4 Submission of Matters to a Vote of Security Holders 10
Item 5 Other Information 10
PART III - OTHER
Item 6. Exhibits and Reports on Form 8-K 10
Signature 11
NATURAL HEALTH TRENDS CORP.
CONSOLIDATED BALANCE SHEET
(UNAUDITED)
June 30,
2001
------------------
ASSETS
Current Assets:
Cash $1,481,285
Restricted cash 66, 784
Account receivables 873,816
Inventories 503,806
Prepaid expenses and other current assets 51,377
------------------
Total Current Assets 2,977,068
Property and Equipment, net 54,899
Deposits and Other Assets 134,127
------------------
Total Assets $ 3,166,094
==================
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Checks written in excess of deposits $ 525,416
Accounts payable 1,386,205
Reserve for contingent liability 3,110,023
Accrued expenses 678,436
Accrued bonus payable 526,829
Accrued payroll payable 338,674
Notes payable 286,274
Notes payable related parties 148,274
Deferred revenue 39,354
------------------
Total Current Liabilities 7,039,485
------------------
Stockholders' Deficit:
Preferred stock 3,319,877
Common stock 144,355
Additional paid-in capital 26,731,832
Accumulated deficit (34,069,455)
------------------
Total Stockholders' Deficit (3,873,391)
------------------
Total Liabilities and Stockholders' Deficit $ 3,166,094
==================
See Notes to Consolidated Financial Statements.
1
NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months Ended June 30, Six Months Ended June 30,
2001 2000 2001 2000
-------------- ------------- --------------- ------------
Revenues $ 9,824,203 $ 1,768,454 $ 13,010,051 $ 4,954,672
Cost of Sales 2,769,023 463,854 3,408,300 1,146,051
-------------- ------------- --------------- ------------
Gross Profit 7,055,180 1,304,600 9,601,751 3,808,621
Distributor commissions 4,786,743 823,313 6,453,637 2,119,218
Selling, general and administrative expenses 1,050,000 1,325,529 1,793,655 2,559,639
-------------- ------------- --------------- ------------
Operating income (loss) 1,218,437 (844,242) 1,354,459 (870,236)
Minority interest in loss of subsidiary - 64,536 - 64,536
Gain (Loss) on foreign exchange (200) (19,086) (244) (16,445)
Other (expense) income 37,989 (26,149) 35,009 -
Interest (net) (3,118) (11,286) (15,534) (18,200)
-------------- ------------- --------------- ------------
Net income (loss) from continuing operations 1,253,108 (836,227) 1,373,690 (840,345)
Discontinued Operations:
Loss from discontinued operations - (4,822) - (4,822)
-------------- ------------- --------------- ------------
Net income (loss) 1,253,108 (841,049) 1,373,690 (845,167)
Preferred stock dividends 124,886 (624,899) 230,929 204
-------------- ------------- --------------- ------------
Net income (loss) to common shareholders $ 1,128,222 $ (216,150) $ 1,142,761 $ (845,371)
============== ============= =============== ============
Basic income (loss) per common share $ 0.04 $ (0.02) $ 0.04 $ (0.10)
============== ============= =============== ============
Basic weighted common shares used 59,245,565 8,754,116 29,622,783 8,754,116
============== ============= =============== ============
Diluted income (loss) per common share $ 0.01 $ (0.02) $ 0.01 $ (0.10)
============== ============= =============== ============
Diluted weighted common shares used 190,126,367 8,754,116 160,408,421 8,754,116
============== ============= =============== ============
See Notes to Consolidated Financial Statements.
2
NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
June 30,
---------------------------
2001 2000
------------- ------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ 1,373,690 $ (845,167)
-------------- -----------
Adjustments to reconcile net income (loss)
to net cash provided by (used in)
operating activities:
Depreciation and amortization 39,589 261,871
Issuance of common stock in settlement of
interest - 78,565
Changes in assets and liabilities
Increase in accounts receivable (822,048) (207,732)
(Increase) decrease in inventories (306,737) 258,834
Increase in prepaid expenses (33,785) (9,678)
(Increase) decrease in deposits and other assets 52,912 (42,744)
Increase in accounts payable, cash overdraft
and reserve for contingent liability 1,374,709 287,052
Increase (decrease) in accrued expenses (54,196) 381,434
Decrease in deferred compensation - 55,964
Decrease in deferred revenue (80,061) (527,831)
Decrease in other current liabilities (331,195) (31,410)
-------------- -----------
Total Adjustments 49,052 506,718
-------------- -----------
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 1,324,639 (338,449)
-------------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (24,635) -
Proceeds from sale of fixed assets - 10
Business acquisitions, net of cash acquired - (208,203)
Decrease in restricted cash 6,050 86,181
-------------- -----------
NET CASH USED IN INVESTING ACTIVITIES (18,586) (122,012)
-------------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from preferred stock 50,000 1,000,000
Proceeds from notes payable and long-term debt 50,000 39,701
Payments of notes payable and long-term debt (33,187) (235,493)
Redemption of preferred stock - (359,153)
-------------- ----------
NET CASH PROVIDED BY FINANCING ACTIVITIES 66,813 445,055
-------------- ----------
NET INCREASE (DECREASE) IN CASH 1,372,866 (15,406)
CASH, BEGINNING OF PERIOD 108,419 434,063
-------------- ----------
CASH, END OF PERIOD $ 1,481,285 $ 418,657
============== ==========
See notes to consolidated financial statements.
3
NATURAL HEALTH TRENDS CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SIX MONTHS ENDED JUNE 30, 2001
(UNAUDITED)
1. BASIS OF PRESENTATION
The accompanying unaudited financial statements of Natural Health Trends
Corp. (the "Company") have been prepared in accordance with generally
accepted accounting principles for interim financial information and with
instructions to Form 10-QSB and Article 10 of Regulation S-X. Accordingly,
they do not include all of the information and footnotes required by
generally accepted accounting principles for complete financial statements.
In the opinion of management, all adjustments considered necessary for a
fair presentation (consisting of normal recurring accruals) of financial
position and results of operations for the interim periods have been
presented. The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date
of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from
those estimates. Operating results for the six month period ended June 30,
2001 are not necessarily indicative of the results that may be expected for
the year ending December 31, 2001. For further information, refer to the
consolidated financial statements and footnotes thereto included in the
Company's Annual report on Form 10-KSB for the year ended December 31,
2000.
The Company had a working capital deficiency of approximately $4,062,000 at
June 30, 2001 and $5,865,000 at December 31, 2000. We recorded a net loss
of approximately $11,947,000 for the year ended December 31, 2000. This
raises substantial doubt about the Company's ability to continue as a going
concern. The Company's continued existence is dependent on its ability to
generate profits from operations. While we are unable to predict
profitability and can make no assurances, we believe we will generate
sufficient profits to ease our dependency on debt and equity financing in
the foreseeable future.
2 FUTURE EFFECTS OF RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In June 2001, the Financial Accounting Standards Board issued Statements of
Financial Accounting Standards No. 141, Business Combinations, and No. 142,
Goodwill and Other Intangible Assets, effective for fiscal years beginning
after December 15, 2001. Under the new rules, goodwill and intangible
assets deemed to have indefinite lives will no longer be amortized but will
be subject to annual impairment tests in accordance with the Statements.
Other intangible assets will continue to be amortized over their useful
lives. The Company will apply the new rules on accounting for goodwill and
other intangible assets beginning in the first quarter of 2002. Application
of the non-amortization provisions of the Statement are not expected to
have a material effect on the Company's financial position or operations.
4
3. During the first six months of 2001, the Company received notice of
conversion on 2,482,533 shares of Series E, F, G, and H Preferred Stock.
The Company issued 103,458,541 shares of common stock in settlement of the
shares of Preferred Stock and the accrued dividends thereon. The following
table sets forth the conversions and the stock price thereof as of the date
of conversion.
Preferred stock Preferred Common stock
Series Conversion stock face Conversion
Converted Date value price
E 4-Jan-01 5,236 .01005
E 18-Jan-01 3,898 .0075
E 22-Jan-01 3,974 .00765
E 23-Jan-01 5,452 .0105
E 24-Jan-01 7,476 .0144
E 8-Feb-01 6,990 .0129
E 17-Feb-01 12,856 .01194
E 25-Mar-01 23,008 .010965
E 12-Mar-01 5,800 .01125
F 17-Feb-01 172,118 .02359
F 25-Mar-01 30,000 .019
G 17-Jan-01 16,000 .0095
G 27-Feb-01 13,000 .01425
G 26-Feb-01 21,000 .0114
G 25-Mar-01 14,400 .0114
G 31-Mar-01 17,000 .01235
H 5-Feb-01 19,132 .0125
H 31-Mar-01 31,561 .0100
H 4-Apr-01 30,000 .0105
H 5-Apr-01 13,300 .0125
G 5-Apr-01 33,000 .0133
F 5-Apr-01 25,000 .0133
E 6-Apr-01 7,846 .0153
F 6-Apr-01 15,000 .0133
H 11-Apr-01 52,749 .0185
E 11-Apr-01 153,886 .0336
E 21-Apr-01 290,982 .038775
H 21-Apr-01 150,000 .0453
F 21-Apr-01 60,000 .02337
H 1-May-01 67,799 .0418
F 13-May-01 60,000 .055125
E 7-May-01 246,939 .0665
G 5-Jun-01 229,800 .02375
F 5-Jun-01 495,000 .052
F 25-Jun-01 142,330 .01463
5
4. We sold 100% of our stock in Kaire Nutraceuticals, Inc. to a South
African firm in June 2001. The agreement includes an earn out over five
years with a minimum of $50,000 per year. We have fully reserved any gain
that may have been recognized for contingent liabilities associated with
the sale.
5. In April 2000, we issued an additional $50,000 of Series H Preferred Stock.
6. In April 2001, we issued a promissory note for $50,000, due on demand
bearing interest at 10% per annum
7. We issued 3,000,000 shares of common stock in connection with the Founder's
Agreement in April 2001, in the start-up phase of Lexxus International. In
connection with this agreement, we will issue up to an additional 7,000,000
shares of common stock to the founding partners of Lexxus International,
Inc.
8. In April 2001 we issued 200,000 shares of common stock to an individual for
lending us $50,000.
9. The Company increased the number of authorized shares to 500,000,000 common
stock, par $.001, in January 2001 by a majority vote of the Board of
Directors in order to meet it's obligations with respect to convertible
securities.
10. We issued 500,000 shares of common stock to certain management employee's
of our subsidiaries in April 2001 and recorded $7,240 of compensation
expense.
Item 2.Management's Discussion and Analysis or Plan of Operations
The following discussions should be read in conjunction with the
consolidated financial statements and notes contained in Item 1 hereof.
Forward Looking Statements
When used in Form 10-QSB and in future filings by the Company with the
Securities and Exchange Commission, the words "will likely result", "the
Company expects", "will continue", "is anticipated", "estimated",
"projected", "outlook" or similar expressions are intended to identify
"forward- looking statements" within the meaning of the Private Securities
Litigation Act of 1995. The Company wishes to caution readers not to place
undue reliance on such forward-looking statements, each of which speak only
as of the date made. Such statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from
historical earnings and those presently anticipated or projected. The
Company has no obligation to publicly release the results of any revisions
which may be made to any forward-looking statements to reflect anticipated
or unanticipated events or circumstances occurring after the date of such
statements.
Overview
In February 1999, the Company acquired the assets of Kaire International,
Inc. and commenced marketing and distributing a line of natural, herbal
based dietary supplements and personal care products through an established
network marketing system. During 1999, the Company ceased operations of
Global Health Alternatives ("GHA") and in March 2001 filed for Chapter 7
Bankruptcy protection in U.S. Federal Court, North Dallas. In January 2001
we launched Lexxus International, Inc., a majority owned subsidiary and
commenced marketing and distributing a line of woman's topical cream that
assists in sexual stimulation.
We sold 100% of our stock in Kaire Nutraceuticals, Inc. to a South African
firm in June 2001. The agreement includes an earn out over five years with
a minimum of $50,000 per year. We have fully reserved any gain that may
have been recognized for contingent liabilities associated with the sale.
6
Six Months Ended June 30, 2001 Compared To The Six Months Ended June 30, 2000.
Net Sales. Net sales were approximately $13,010,000 and $4,955,000 for the
six months ended June 30, 2001 and June 30, 2000 respectively; an increase
of $8,055,000 or 162.6%. Sales for eKaire.com declined approximately
$2,461,000 which was offset by sales of Lexxus International of
approximately $10,516,000.
Cost of Goods Sold. Cost of goods sold for the six months ended June 30,
2001 was approximately $3,408,000 or 26.2% of net sales. Cost of goods sold
for the six months ended June 30, 2000 was approximately $1,146,000 or
23.1% of net sales. The total cost of goods sold increased by approximately
$2,262,000 or 197.4% due to increased costs associated with the packaging
of the Lexxus product line.
Gross Profit. Gross profit increased from approximately $3,809,000 in the
six months ended June 30, 2000 to approximately $9,602,000 in the six
months ended June 30, 2001. The increase was approximately $5,793,000 or
152.1%. The increase was attributable to higher sales volume in our Lexxus
subsidiary.
Commissions. Associate commissions were approximately $6,454,000 or 49.6%
of net sales in the six months ended June 30, 2001 compared to
approximately $2,119,000 or 42.8% of net sales for the six months ended
June 30, 2000. This increase is attributable to the higher payout
percentage associated with the Lexxus compensation plan.
Selling, General and Administrative Expenses. Selling, general and
administrative costs decreased from approximately $2,560,000 or 51.7% of
sales in the six months ended June 30, 2000 to approximately $1,794,000 or
13.8% of sales in the six months ended June 30, 2001, a decrease of
approximately $766,000 or 29.9%. The decrease is due primarily to eKaire's
reduction of expenses and Lexxus sharing overhead in its start-up phase.
Income (loss)from Operations. Operating income (loss) decreased from a loss
of approximately $870,000 in the six months ended June 30, 2000 to
operating income of approximately $1,354,000 in the six months ended June
30, 2001 representing a 255.6% increase in operating income comparable
periods.
Gain (Loss) on Foreign Exchange. The Company operates subsidiaries in
Australia and New Zealand. During the six months ended June 30, 2001, the
net loss on foreign exchange adjustments was $244 compared to a net loss of
approximately $16,000 in the six months ended June 30, 2000.
Other Income (expenses). Other expenses of approximately $18,000 or 0.4% of
sales in the six months ended June 30, 2000 decreased to other income of
approximately $19,000 or 0.1% of sales in the six months ended June 30,
2001, a change of approximately $38,000. This increase is due primarily to
an decrease in interest bearing liabilities and an increase in interest
bearing assets.
Income Taxes. Income tax benefits were not reflected in either period. The
anticipated benefits of utilizing net operating losses against future
profits was not recognized in the six months ended June 30, 2001 or the six
months ended June 30, 2000 under the provisions of Financial Standards
Board Statement of Financial Accounting Standards No. 109 (Accounting for
Income Taxes), utilizing its loss carryforwards as a component of income
tax expense. A valuation allowance equal to the net deferred tax asset has
been recorded, as management of the Company has not been able to determine
that it is more likely than not that the deferred tax assets will be
realized.
Net Income (Loss). Net income from continuing operations was approximately
$1,374,000 in the six months ended June 30, 2001 or 10.6% of net sales as
compared to a loss of approximately $840,000 or 17.0% of net sales in the
six months ended June 30, 2000.
7
Liquidity and Capital Resources:
We have funded our working capital and capital expenditure requirements
primarily from cash provided through borrowings from institutions and
individuals, and from the sale of our securities in private placements. Our
other ongoing source of cash receipts has been from the sale of eKaire.com
and Lexxus products.
In February 1998, we issued $300,000 face amount of Series B Preferred
Stock, net of expenses of $38,500. The Series B Preferred Stock has been
converted into 541,330 shares of common stock.
In April 1998, we issued $4,000,000 face amount of Series C Preferred
Stock, net of expenses of $492,500 from the proceeds raised, we paid
$2,500,000 to retire $1,568,407 face value of Series A Preferred Stock
outstanding. The Series C Preferred Stock has been converted into 3,608,296
shares of common stock.
In August 1998, we issued $1,650,000 face amount of Series E Preferred
Stock, net of expenses of $210,500. The Series E Preferred Stock pays
dividends of 10% per annum and is convertible into shares of common stock
at the lower of the closing bid price on the date of issue or 75% of the
market value of the common stock. In September 1999, $610,000 of face
amount of Series E Preferred Stock was converted into 603,130 shares of
common stock. During the first six months of 2001, $774,343 of face amount
Series E Preferred Stock was converted into 28,456,082 shares of common
stock.
In March and April 1999, we issued $1,400,000 of Series H Preferred Stock.
The Series H Preferred Stock pays dividends of 10% per annum and is
convertible into shares of common stock at the lower of the closing bid
price on the date of issue or 75% of the market value of the common stock.
In the first six months of 2001, $364,542 of face amount of Series H
Preferred Stock were converted into 14,403,722 shares of the Company's
common stock. In April 2001, we issued an additional $50,000 of Series H
Preferred Stock.
During the Six months ended June 30, 2001 we converted $999,448 shares of
Series F Preferred stock into 40,893,970 shares of the Company's common
stock.
During the Six months ended June 30, 2001 we converted $344,200 shares of
Series G Preferred stock into 15,732,164 shares of the Company's common
stock. These transactions fully retired the Series G Preferred Stock.
In June 1999, we borrowed $100,000 from Domain Investments, Inc. The loan
bears interest at 10% per annum and is payable on demand. The note is
convertible into shares of common stock at a discount equal to 60% of the
average closing bid price of the common stock on the three days preceding
notice of conversion. This note has been fully satisfied through conversion
to common stock during the six months ended June 30, 2001.
In July and August 1999 we borrowed $150,000 from Filin Corporation, and
issued a secured promissory note due on the earlier of 60 days from the
date of issuance or upon the sale of its securities resulting in gross
proceeds of at least $5,000,000 and bearing interest at the rate of 10% per
annum, but in no event less than $12,000. In October 1999 we amended the
promissory note to provide that the note is payable upon demand and is
convertible into shares of common stock at a discount equal to 60% of the
average closing bid price of the common stock on the three days preceding
notice of conversion.
In October 1999, we borrowed $100,000 from Domain Investments, Inc. The
loan bears interest at 10% per annum and is payable on demand. The note is
convertible into shares of common stock at a discount equal to 60% of the
average closing bid price of the common stock on the three days preceding
notice of conversion. This note has been fully satisfied through conversion
to common stock during the six months ended June 30, 2001.
8
In March 2000, we sold 1,000 shares of Series J Preferred Stock with a
stated value of $1,000 per share realizing net proceeds of $1,000,000. The
preferred stock pays a dividend at the rate of 10% per annum. The preferred
stock and the accrued dividends thereon are convertible into shares of the
Company's common stock at a conversion price equal to the lower of the
closing bid price on the date of issuance or 70% of the average closing bid
price of the common stock for the lowest three trading days during the
twenty day period immediately preceding the date on which the Company
receives notice of conversion from a holder. In connection with the
offering of the Series J Preferred Stock, the Company issued warrants to
purchase 141,907 shares of common stock at an exercise price of $1.41 per
share.
In February 2001 we borrowed $50,000 from an individual. The loan bears
interest at 12% interest per annum and was due in April. We have received
an extension on repayment until September 2001.
At June 30, 2001, our ratio of current assets to current liabilities was
.42 to 1.0 and we had a working capital deficit of approximately
$4,062,000.
Cash provided by operations for the six months ended June 30, 2001 was
approximately $1,325,000 primarily related to operating profits. Cash used
in investing activities during the period was approximately $19,000, which
primarily relates to the increase of in fixed assets associated with our
Lexxus subsidiary. Cash provided by financing activities during the period
was approximately $66,000, primarily from a private borrowing of
approximately $50,000 and proceeds from Series H Preferred stock issued and
partially offset by the repayment of certain notes payable of approximately
$33,000. Total cash increased by approximately $1,373,000 during the
period.
Our independent auditors' report on our consolidated financial statements
stated as of December 31, 2000 due to net losses and a working capital
deficit, there is substantial doubt about the company's ability to continue
as a going concern. Our subsidiary, Global Health Alternatives filed for
Chapter 7 Bankruptcy protection and received a discharge of all debt in the
second quarter of 2001. While there can be no assurances, management
believes that the profitability achieved during the six months ended June
30, 2001 will continue for the foreseeable future.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
None.
Item 2. Changes in Securities and Use of Proceeds
The Company received 26 notices of conversion on its Series E Preferred
Stock during the six months ended June 30, 2001 and redeemed $774,343, face
value in exchange for 28,456,082 shares of the Company's common stock.
The Company received 16 notices of conversion on its Series F Preferred
Stock during the six months ended June 30, 2001 and redeemed $999,448, face
value in exchange for 40,893,970 shares of its common stock.
The Company received 14 notices of conversion on its Series G Preferred
Stock during the six months ended June 30, 2001 and redeemed $344,200, face
value in exchange for 15,732,164 shares of its common stock.
The Company received 7 notices of conversion on its Series H Preferred
Stock during the six months ended June 30, 2001 and redeemed $136,771, face
value in exchange for 10,067,590 shares of its common stock. In addition,
we issued 200,000 shares of common stock as consideration for the $50,000
of face value Series H Preferred Stock issued in April 2001.
9
We issued 3,000,000 shares of common stock in connection with the Founder's
Agreement in April 2001, in the start-up phase of Lexxus International. In
connection with this agreement, we will issue up to an additional 7,000,000
shares of common stock to the founding partners of Lexxus International,
Inc.
In April 2001 we issued 200,000 shares of common stock to an individual for
lending us $50,000. (See Liquidity and Capital Resources).
We issued 500,000 shares of common stock to certain management employees in
April 2001.
The Company increased the number of authorized shares to 500,000,000 common
stock, par $.001, in January 2001 by a majority vote of the Board of
Directors in order to meet it's obligations with respect to convertible
securities.
Item 3. Defaults upon Senior Securities
None
Item 4. Submission of Matters to Vote of Security Holders
None
Item 5. Other Information
None
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
None
(b) Reports on Form 8-K
None
10
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NATURAL HEALTH TRENDS CORP.
By: /s/ Mark D. Woodburn
-----------------------
Mark D. Woodburn
President
Date: August 12, 2001
11